tbuckley/cabot-search huggingface dataset:
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013
Authors: Jeffrey D Stanaway, Abraham D Flaxman, Mohsen Naghavi, Christina Fitzmaurice, Theo Vos, Ibrahim Abubakar, Laith J Abu-Raddad, Reza Assadi, Neeraj Bhala, Benjamin Cowie, Mohammad H Forouzanfour, Justina Groeger, Khayriyyah Mohd Hanafiah, Kathryn H Jacobsen, Spencer L James, Jennifer MacLachlan, Reza Malekzadeh, Natasha K Martin, Ali A Mokdad, Ali H Mokdad, Christopher J L Murray, Dietrich Plass, Saleem Rana, David B Rein, Jan Hendrik Richardus, Juan Sanabria, Mete Saylan, Saeid Shahraz, Samuel So, Vasiliy V Vlassov, Elisabete Weiderpass, Steven T Wiersma, Mustafa Younis, Chuanhua Yu, Maysaa El Sayed Zaki, Graham S Cooke
Journal: The Lancet (2016)
Genome-wide association study using whole-genome sequencing rapidly identifies new genes influencing agronomic traits in rice
Authors: Kenji Yano, Eiji Yamamoto, Koichiro Aya, Hideyuki Takeuchi, Pei-ching Lo, Li Hu, Masanori Yamasaki, Shinya Yoshida, Hidemi Kitano, Ko Hirano, Makoto Matsuoka
Journal: Nature Genetics (2016)
Sternal Uptake of 99mTc-MAA in Thoracic Outlet Syndrome
Authors: Yohji Matsusaka, Tadaki Nakahara, Yu Iwabuchi, Masashi Kameyama, Koji Murakami
Journal: Clinical Nuclear Medicine (2015)

Tc-macroaggregated albumin (MAA) uptake in the vertebrae has been reported in central vein occlusion, although its sternal uptake is rarely seen. We present a case in which Tc-MAA SPECT/CT showed spotty uptake in the sternum. Contrast-enhanced CT revealed marked narrowing of the left subclavian vein at the thoracic outlet with a developed collateral vein running, in the left anterior chest subcutaneous tissue, between the sternum and left axilla. In this case, IV injection of Tc-MAA from the left forearm probably led to bone marrow uptake in the sternum due to retrograde venous flow through the collateral vein.
Incidental Detection of Urinary Leakage on FDG PET/CT Imaging for Staging of Gastric Cancer
Authors: Dae-Weung Kim, Myoung Hyoun Kim, Chang Guhn Kim
Journal: Clinical Nuclear Medicine (2015)

A 71-year-old woman presented to the emergency department with right flank pain and dysuria. An abdominal CT scan detected a gastric malignancy and hydronephrosis with urinary leakage of the right kidney. Percutaneous nephrostomy was performed on the right kidney. 18F-FDG PET/CT for staging the gastric malignancy revealed additional urinary leakage of the contralateral kidney. The interest in this case is the incidental detection of unexpected urinary leakage during an oncologic assessment with FDG PET/CT.
Liver resection for metastases from colorectal cancer in very elderly patients: New surgical horizons
Authors: Bruno Nardo, Simone Serafini, Michele Ruggiero, Raffaele Grande, Francesco Fugetto, Alessandra Zullo, Matteo Novello, Antonia Rizzuto, Elisabetta Bonaiuto, Sebastiano Vaccarisi, Giuseppe Cavallari, Raffaele Serra, Marco Cannistrà, Rosario Sacco
Journal: International Journal of Surgery (2016)
Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia.
Authors: Tamara Maes, Iñigo Tirapu, Cristina Mascaró, Alberto Ortega, Angels Estiarte, Nuria Valls, Julio Castro-Palomino, Carlos Buesa Arjol, Guido Kurz
Journal: Journal of Clinical Oncology (2013)

e13543 Background: The lysine-specific demethylase KDM1A catalyzes the removal of methyl groups from mono and dimethylated H3K4/K9, changes that have inductive or inhibitory effects on gene expression. KDM1A is a key regulator of leukemia stem cell (LSC) potential and is required for MLL-AF9 oncogenic transformation. Inhibition of KDM1A expression or activity overcomes the differentiation block in AML. Mixed lineage leukemia (MLL) is a form of AML that is especially sensitive to inhibition of KDM1A. Methods: Gene expression was analyzed using microarrays, cell differentiation was assessed by FACS, viability and apoptosis were assessed by MTT assay and PI staining, me 2 H3K4 levels were quantified by qPCR and ChIPseq. Results: We used computational models based on reported X-ray structures fine-tuned with the SAR of a first series of molecules to design and synthesize &gt;800 KDM1A inhibitors. ORY-1001 is an enantiomerically pure KDM1A inhibitor (IC50 &lt;20nM) with high selectivity against related FAD dependent aminoxidases (MAO-A/B, IL4I1, KDM1B &gt;100uM, SMOX 7uM). ORY-1001 does not inhibit non-related histone modifiers, and is clean in a CEREP diversity panel. Treatment of THP-1 (MLL-AF9) cells with ORY-1001, results in a time/dose dependent me 2 H3K4 accumulation at KDM1A target genes and concomitant induction of differentiation markers (EC50 me 2 H3K4 and FACS CD11b &lt;1nM). Microarray analysis of treated THP-1 cells reveals differentiation towards a monocyte-like phenotype. ORY-1001 induces apoptosis in THP-1 and inhibits proliferation and colony formation of MV(4;11) (MLL-AF4) cells (EC50 &lt;1nM). Daily oral administration of doses &lt;0.020mg/kg leads to significantly reduced tumor growth in rodent MV(4;11) xenografts. In vivo and in vitro IND/IMPD enabling studies have shown that ORY-1001 presents excellent oral bioavailability, target exposure and activity in vivo. The compound is stable in hepatocytes (Clint&lt;0.6 mL/min/g liver, @1uM) and does not exhibit CYP (IC 50 &gt;100uM) or hERG (%inhib.&lt;2%, @10uM) inhibition. No off-target activity has been detected in 28d rat toxicology studies. Conclusions: A potent and selective KDM1A inhibitor is described with in vitro and vivo anti-leukemic efficacy.
Malignant Transformation of Hamster Brain Cells in Vitro by Human Papovavirus BK 2
Authors: Ryuichi Tanaka, Hilary Koprowski, Yuzo Iwasaki
Journal: JNCI Journal of the National Cancer Institute (1976)

Human papovavirus BK caused the malignant transformation in vitro of brain cells pr~pared from newborn hamsters. The transformed cells produced BK virus T antigen and grew as tumors after sc inoculation into hamsters that developed antibodies to BK virus T antigen. The histopathology of the tumors revealed an undifferentiated glioma.
Case 19-1969
Authors: Stephen E. Goldfinger, Austin L. Vickery
Journal: New England Journal of Medicine (1969)

Presentation of CaseA sixty-one-year-old man was admitted to the hospital because of anorexia, weakness and weight loss.He had been well until four months before entry, when diffuse abdominal discomfort developed. He remained well and active, continuing to play golf, until four weeks before entry. At that time anorexia occurred, with a weight loss from 165 to 151 pounds during the next four weeks. He experienced progressive weakness, and walking became difficult. During the week before entry there was the onset of diarrhea, with the passage of 5 or 6 loose, brown stools daily; there was no melena or . . .
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group
Authors: F Theis, A Corbacioglu, V I Gaidzik, P Paschka, D Weber, L Bullinger, M Heuser, A Ganser, F Thol, B Schlegelberger, G Göhring, C-H Köhne, U Germing, P Brossart, H-A Horst, D Haase, K Götze, M Ringhoffer, W Fiedler, D Nachbaur, T Kindler, G Held, M Lübbert, M Wattad, H R Salih, J Krauter, H Döhner, R F Schlenk, K Döhner
Journal: Leukemia (2016)
Characteristic Pulvinar Sign in Pseudo-α-galactosidase Deficiency Syndrome
Authors: Salman Farooq, Bradley C. Hiner, William J. Rhead, Alison La Pean Kirschner, Thomas C. Chelimsky
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging
Authors: Aleksandar Denic, John C. Lieske, Harini A. Chakkera, Emilio D. Poggio, Mariam P. Alexander, Prince Singh, Walter K. Kremers, Lilach O. Lerman, Andrew D. Rule
Journal: Journal of the American Society of Nephrology (2016)

Nephron number may be an important determinant of kidney health but has been difficult to study in living humans. We evaluated 1638 living kidney donors at Mayo Clinic (MN and AZ sites) and Cleveland Clinic. We obtained cortical volumes of both kidneys from predonation computed tomography scans. At the time of kidney transplant, we obtained and analyzed the sections of a biopsy specimen of the cortex to determine the density of both nonsclerotic and globally sclerotic glomeruli; the total number of glomeruli was estimated from cortical volume×glomerular density. Donors 18-29 years old had a mean 990,661 nonsclerotic glomeruli and 16,614 globally sclerotic glomeruli per kidney, which progressively decreased to 520,410 nonsclerotic glomeruli per kidney and increased to 141,714 globally sclerotic glomeruli per kidney in donors 70-75 years old. Between the youngest and oldest age groups, the number of nonsclerotic glomeruli decreased by 48%, whereas cortical volume decreased by only 16% and the proportion of globally sclerotic glomeruli on biopsy increased by only 15%. Clinical characteristics that independently associated with fewer nonsclerotic glomeruli were older age, shorter height, family history of ESRD, higher serum uric acid level, and lower measured GFR. The incomplete representation of nephron loss with aging by either increased glomerulosclerosis or by cortical volume decline is consistent with atrophy and reabsorption of globally sclerotic glomeruli and hypertrophy of remaining nephrons. In conclusion, lower nephron number in healthy adults associates with characteristics reflective of both lower nephron endowment at birth and subsequent loss of nephrons.
Elevated 99mTc-MDP and 18F-NaF Uptake in a Bladder Stone
Authors: Yuting Zou, Yue Chen, Zhanwen Huang, Liang Cai, Fuqiang Shao
Journal: Clinical Nuclear Medicine (2016)

An 82-year-old man with known Eddison disease, osteoporosis, and a right buttock soft tissue mass underwent Tc-MDP bone scintigraphy with SPECT/CT and F-NaF PET/CT, both of which showed elevated uptake in a bladder stone.
Response to: ‘Biologic agents for giant cell arteritis: treat to target’ by Moiseev <i>et al</i>
Authors: Richard Conway, Eamonn S Molloy
Journal: Annals of the Rheumatic Diseases (2016)

We thank Moiseev et al for their interest in our study of ustekinumab in giant cell arteritis (GCA).1 ,2 Our pilot study reported promising initial results from the use of ustekinumab in GCA.1

GCA is a potentially devastating disease with cranial ischaemic complications such as blindness and stroke occurring in 20%–25% of patients.3 While corticosteroids are effective in reducing the risk of cranial ischaemic complications, they do not fully extinguish the vascular inflammation in patients with GCA4–6 with consequent risk of disease relapse and longer-term consequences such as …
Sensitivity of immunohistochemical detection of EGFR could impact patient eligibility for anti-EGFR therapy
Authors: C. H. Tse, D. O. Treaba, L. C. Goldstein, P. L. Kandalaft, T. S. Barry, A. M. Gown
Journal: Journal of Clinical Oncology (2005)

3607 Background: Immunohistochemical detection of EGFR expression has been employed for selecting patients with advanced colorectal cancer for anti-EGFR therapy. Using the FDA approved EGFR pharmDx kit (DakoCytomation), the reported EGFR positivity rates in colonic adenocarcinoma ranged from 72.8% to 82.1%. We evaluated an alternative anti-EGFR monoclonal antibody to determine its sensitivity relative to the EGFR pharmDx kit and estimated the potential impact on patient eligibility for anti-EGFR therapy. Methods: A series of 186 cases of colorectal cancer were tested for EGFR expression using two different monoclonal anti-EGFR antibodies: clone 2–18C9 (pharmDx-Ab) from DakoCytomation, and clone 31G7 (Zymed-Ab) from Zymed Laboratories. In both cases, the FDA-approved criteria were applied for scoring EGFR positivity, defined as >1% tumor cells showing specific membranous immunostaining. The cases were scored by a single pathologist. A subset of negative/low-scoring cases were then selected for re-scoring by three pathologists independently to verify the difference in sensitivity of the two antibodies. Results: 132/186 (71%) cases were EGFR positive using pharmDx-Ab, and 155/186 (83.3%) cases were positive using the Zymed-Ab. 24 of 54 (44.4%) cases classified as negative using pharmDx-Ab were reclassified as positive using the Zymed-Ab. On the set of 80 negative/low-scoring cases, all three pathologists observed a higher positivity rate with Zymed-Ab and 56.8% to 64.1% of the EGFR pharmDx negative cases were reclassified as positive with Zymed-Ab. Conclusions: Immunohistochemical expression of EGFR is currently used to determine patient eligibility for anti-EGFR therapy in colorectal adenocarcinoma. Thus the sensitivity of the antibody used in IHC screening of tumors is critical. This study shows that the Zymed-Ab is significantly more sensitive than the pharmDx-Ab and would identify 10–15% more patients eligible for anti-EGFR therapy. No significant financial relationships to disclose.
Chronic exertional compartment syndrome
Authors: Steven N Shah, Bruce S Miller, John E Kuhn
Journal: BMJ (2013)

Chronic exertional compartment syndrome is an overuse condition affecting primarily active, athletic people. Its etiology is unclear, but several theories have been proposed. The syndrome is characterized by recurrent, often severe muscle compartment pain that occurs with vigorous exercise and subsides with rest. Physical examination usually provides little helpful information. Compartment pressure measurement before and after exercise is the mainstay of objective diagnosis. Conservative management has been highly unsuccessful. Overall, considerable success can be expected from fasciotomy of the involved compartments followed by a rigorous rehabilitation program, though recurrence of symptoms is a reported complication. Recent research efforts have focused on the development of less invasive and more accurate diagnostic modalities and safer and more effective surgical procedures.
E-cigarettes may be reversing fall in teenage smoking, study finds
Authors: Susan Mayor
Journal: BMJ (2016)

Experimenting with electronic cigarettes may be reversing the previous long term decline in teenage smoking, a US study has shown.1

Adolescent e-cigarette use has increased rapidly in recent years, but it is unclear whether e-cigarettes are merely replacing cigarettes or whether they are being used by people who would not otherwise have smoked.

The study investigated tobacco use in five groups of teenagers who …
Methods for Quantitative Bioassay of Ehrlich Ascites-Tumor Cells&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Alfred M. Prince, Arthur S. Littell, Harold S. Ginsberg
Journal: JNCI Journal of the National Cancer Institute (1957)

Methods for Quantitative Bioassay of Ehrlich Ascites-Tumor Cells Get access Alfred M. Prince, Alfred M. Prince Department of Preventive Medicine and Department of Medicine, School of Medicine, Western Reserve University, and the University Hospitals, Cleveland, Ohio Search for other works by this author on: Oxford Academic PubMed Google Scholar Arthur S. Littell, Arthur S. Littell Department of Preventive Medicine and Department of Medicine, School of Medicine, Western Reserve University, and the University Hospitals, Cleveland, Ohio Search for other works by this author on: Oxford Academic PubMed Google Scholar Harold S. Ginsberg Harold S. Ginsberg Department of Preventive Medicine and Department of Medicine, School of Medicine, Western Reserve University, and the University Hospitals, Cleveland, Ohio Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 18, Issue 4, April 1957, Pages 487–506, https://doi.org/10.1093/jnci/18.4.487 Published: 01 April 1957 Article history Received: 02 November 1956 Published: 01 April 1957
Re: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non Small-Cell Lung Cancer
Authors: F. Leo, T. De Pas, G. Catalano, G. Piperno, G. Curigliano, P. Solli, G. Veronesi, F. Petrella, L. Spaggiari
Journal: JNCI Journal of the National Cancer Institute (2007)
Case 40-1968
Authors: Carroll B. Larson, Benjamin Castleman
Journal: New England Journal of Medicine (1968)

Presentation of CaseA forty-six-year-old man was admitted to the hospital because of pain in the back and hip.Six years previously he had been knocked down by a piece of pipe that fell from a freight car, and a consequent dislocation of the left hip was reduced under general anesthesia at another hospital. Subsequently, he had persistent pain in the left hip. Examination revealed limitation of straight-leg raising on the left side; x-ray films of the left hip were normal. Eight months after the accident a discogram was said to show protrusion of the fourth lumbar disk. Two months . . .
Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial
Authors: Lucas Otieno, Martina Oneko, Walter Otieno, Joseph Abuodha, Emmanuel Owino, Chris Odero, Yolanda Guerra Mendoza, Ben Andagalu, Norbert Awino, Karen Ivinson, Dirk Heerwegh, Nekoye Otsyula, Maria Oziemkowska, Effua Abigail Usuf, Allan Otieno, Kephas Otieno, Didier Leboulleux, Amanda Leach, Janet Oyieko, Laurence Slutsker, Marc Lievens, Jessica Cowden, Didier Lapierre, Simon Kariuki, Bernhards Ogutu, Johan Vekemans, Mary J Hamel
Journal: The Lancet Infectious Diseases (2016)
P-136 Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients
Authors: J.-P. Metges, O. Capitain, F. Ramée Jean, L. Raoul Jean, J.-Y. Douillard, L. Etienne Pierre, I. Cumin, O. Dupuis, R. Faroux, M.-A. Coulon, P. Deguiral, A. Le Rol, E. Achour Nacr, A. Gorlaouen, J.-F. Bouret, F. Marhuenda, D. Déniel Lagadec, F. Grudé
Journal: Annals of Oncology (2016)
Is Body Mass Index a prognostic factor in early-stage breast cancer patients who subsequently developed metastatic disease?
Authors: Apurva Kumari Pandey, Mini Jacob, Louise Mazur, Adam Brufsky, Aju Mathew
Journal: Journal of Clinical Oncology (2015)

e12639 Background: Body Mass Index (BMI) is associated with poor outcomes in early-stage breast cancer (EBC). Analysis of data from three clinical trials found no association between BMI and survival outcomes in metastatic breast cancer (MBC).1 We aimed to evaluate the prognostic role of BMI in patients with EBC who subsequently developed MBC. Methods: We used the University of Pittsburgh cancer registry to retrospectively identify patients diagnosed with EBC between 1998 and 2012, and who subsequently developed MBC. BMI data was obtained at diagnosis of EBC. BMI was categorized based on WHO definition: normal ( < 25Kg/m2), overweight (25-29.9 Kg/m2) and obese ( ≥ 30 Kg/m2). We also obtained demographic information and pertinent prognostic factors such as grade, stage, hormone receptor (HR) and HER2. Overall survival (OS) was defined as time from diagnosis of EBC to death or last follow-up. We used chi-square test for comparison of groups, Kaplan Meir product limit method for survival analysis, and cox regression model for multivariate analysis. Results: Out of 276 patients with EBC who developed MBC, 34.8% had normal BMI, 26.1% were overweight and 39.1% were obese. Median follow-up since diagnosis of EBC was 5.2 years. Median OS was 5.8 years (IQR: 3.5-9.3). Our study population was predominantly Caucasian (93%). 59.4% were HR+ and HER2-, 22.8% were HER2+ and 17.8% were triple negative (TN). Obese and overweight categories had significantly greater median age at diagnosis of EBC (p = 0.01). There were more non-Caucasians in the obese group (p = 0.02). Stage at EBC diagnosis, grade and tumor subtypes were similarly distributed. Median OS was similar in all three BMI categories (log-rank test, p-value > 0.1). In multivariate analysis, there was no association between BMI and OS. Greater age at EBC diagnosis and TN disease were associated with poor survival outcomes. Conclusions: We found no association between BMI categories and survival outcomes in patients with EBC who subsequently developed metastatic disease. Reference: 1. Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1862-7
A Transplantable Ovarian Papillary Adenoearcinoma of the Rat with Ascites Implants in the Ovary
Authors: Alexander Symeonidis, Pablo Mori-Chavez
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article A Transplantable Ovarian Papillary Adenoearcinoma of the Rat with Ascites Implants in the Ovary Get access Alexander Symeonidis, Alexander Symeonidis National Cancer Institute4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar Pablo Mori-Chavez Pablo Mori-Chavez National Cancer Institute4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 2, October 1952, Pages 409–429, https://doi.org/10.1093/jnci/13.2.409 Published: 01 October 1952 Article history Received: 26 May 1952 Published: 01 October 1952
P-080 Incidence of thrombo-embolism (TE) during neo-adjuvant chemotherapy in patients (pts) with oesophago-gastric adenocarcinoma (OGC): implications for surgery and survival
Authors: R. Rulach, J. Evans, D. McIntosh, D. Grose, G. Fullarton, M. Forshaw, C. MacKay, C. Craig, J. Graham
Journal: Annals of Oncology (2016)